COMMUNIQUÉS West-GlobeNewswire

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
21/04/2026
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026 SCOTTSDALE, Ariz., April 21, 2026 (GLOBE NEWSWIRE) -- Journey Medical [...]
Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting
21/04/2026
HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract highlighting data on its lead drug candidate, annamycin, has been [...]
Xeltis releases groundbreaking new 12-month EU pivotal data for aXess™ demonstrating the transformative potential in hemodialysis treatment
21/04/2026
Data demonstrates strong and higher secondary patency compared to conventional arteriovenous grafts (AVG) to meaningfully transform vascular access 79% secondary patency at 12 months in complex patient populations [...]
Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
21/04/2026
· Approval by the Danish Medicines Agency (DKMA) for enrolling patients in Denmark follows the recently announced FDA clearance to initiate the Phase 2b study in the United States. Nes-Ziona, Israel, April 21, 2026 ( [...]
Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting
21/04/2026
Oral presentation will include previously announced topline results as well as pre-specified and post-hoc data updates REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” [...]
AAVantgarde announces completion of recruitment in STELLA natural history study
21/04/2026
MILAN, April 21, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering next-generation gene therapies for inherited retinal diseases (IRDs) has today announced the [...]
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
21/04/2026
Historic U.S. Executive Order Fast-Tracks Psychedelic Research Access; Landmark Policy Shift Strengthens the Outlook for KALA’s Client Red Light Holland and Positions Researgency.ai as the Dedicated AI Infrastructure [...]
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
21/04/2026
120 mg and newly announced 60 mg once-daily doses each achieved ≥85% median hsCRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose levels Phase 2 [...]
RAMSAY SANTE : Half-year Financial Report as at end of December 2025 disposal
21/04/2026
Paris, April 21, 2026 RAMSAY SANTE Half-year Financial Report as at end of December 2025 disposal This document is available on RAMSAY SANTE Internet site : http://www.ramsaysante.fr About Ramsay Santé Ramsay Santé is [...]
BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026
21/04/2026
MAINZ, Germany, April 21, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2026 on Tuesday, May 5, 2026. Additionally, the [...]
Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s Data
21/04/2026
Results showed lasofoxifene protected against hormone withdrawal-induced bone loss and maintained a robust anti-tumor response in primary and metastatic animal models of ER+ breast cancer BOTHELL, Wash., April 21, 2026 [...]
Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026
21/04/2026
New in vivo data demonstrate exceptional selectivity, localization and potency of MDNA113 in the tumor and tumor microenvironment while enhancing the systemic tolerability profile Head-to-head non-human primate [...]
Avricore Health Achieves Milestones and Outlines UK Expansion Roadmap for HealthTab™ Platform
21/04/2026
VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the " Company " or “ Avricore ”) announces HealthTab™ has now screened more than 3,500 patients in community pharmacies [...]
XORTX Meets Nasdaq Continued Listing Requirements
21/04/2026
CALGARY, Alberta, April 21, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on [...]
Amphista Therapeutics presents the discovery, characterisation and chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16 degrader of BRD9 at AACR 2026
21/04/2026
First public disclosure of the chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16-dependent Targeted Glue™ degrader of BRD9 AMX-883 is the Company’s lead asset entering a Phase I [...]
Dark Horse Consulting Group’s Acquisition of CJ PARTNERS Provides Regional Expansion
21/04/2026
WALNUT CREEK, Calif. and TOKYO, April 21, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (“DHCG” or “the Group”) today announced the acquisition of CJ PARTNERS (“CJP”), a distinguished consulting and advisory firm [...]
Preclinical Data of Novel B7-H3 ADC ICP-B794 Unveiled at 2026 AACR, Demonstrating Superior Anti-Tumor Activity and Safety
21/04/2026
BEIJING, April 21, 2026 (GLOBE NEWSWIRE) -- At the 2026 American Association for Cancer Research (AACR) Annual Meeting, InnoCare Pharma (HKEX: 9969; SSE: 688428) presented preclinical data of its novel B7-H3 targeted [...]
Hyalex Orthopaedics Announces FDA 510(k) Clearance of the HYALEX Slalom™ MTP Hemiarthroplasty System
21/04/2026
Regulatory milestone positions company for initial commercial entry into large and underserved foot & ankle market LEXINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Hyalex Orthopaedics today announced that it has [...]
BPGbio Appoints Former Oxford Pro-Vice Chancellor for Innovation Chas Bountra, Ph.D., as Executive Vice President and Chief Scientific Officer
21/04/2026
• Former Oxford Pro-Vice-Chancellor for Innovation and former Head of Biology at GSK to lead company’s R&D • Longstanding Scientific Advisory Board Chair steps into an expanded leadership role to accelerate the [...]

Pages